{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T19:42:25Z","timestamp":1790710945006,"version":"4.1.0"},"reference-count":39,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T00:00:00Z","timestamp":1759795200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Public Health"],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Emicizumab, a bispecific factor IXa- and factor X-directed antibody indicated for routine prophylaxis of bleeding episodes in people with hemophilia A, can impose a significant financial burden. We conducted a systematic review to evaluate the reporting quality of existing pharmacoeconomic studies on emicizumab, and to synthesize its cost-effectiveness for hemophilia A treatment.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Databases including PubMed, Embase, Cochrane Library, National Health Service Economic Evaluation Database, Health Technology Assessment, China National Knowledge Infrastructure, VIP China Science and Technology Journal database, and WanFang were searched for pharmacoeconomic studies on emicizumab. The general information, methods, and results of the retrieved studies were analyzed. The reporting quality of the studies was evaluated with the Consolidated Health Economic Evaluation Reporting Standards (CHEERS) 2022 checklist.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 163 studies were retrieved, and 17 studies were further analyzed. Emicizumab was compared to bypassing agents (BPAs), recombinant factor VIII (rFVIII), recombinant factor VIII Fc fusion protein (rFVIIIFc), and gene therapy. The reporting quality of the studies is generally good with an average score of 79.64% (22.3\/28) based on the CHEERS 2022 checklist. Current studies revealed that emicizumab prophylaxis was more cost-effective compared to BPAs in people with hemophilia A with inhibitors. However, its cost-effectiveness compared to rFVIII was unclear and varied across different countries. In addition, rFVIIIFc and valoctocogene roxaparvovec were more cost-effective than emicizumab for people with HA without inhibitors.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Emicizumab prophylaxis was more cost-effective compared to BPAs in people with hemophilia A with inhibitors. Cost-effectiveness analyses with more accurate cost estimations of different countries should provide more convincing evidence for clinical decision-making.<\/jats:p><\/jats:sec><jats:sec><jats:title>Systematic review registration<\/jats:title><jats:p>Identifier CRD 42023429349, <jats:uri>https:\/\/www.crd.york.ac.uk\/PROSPERO\/view\/CRD42023429349<\/jats:uri>.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fpubh.2025.1658760","type":"journal-article","created":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T05:34:27Z","timestamp":1759815267000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Cost-effectiveness of emicizumab for the treatment of hemophilia A: a systematic review"],"prefix":"10.3389","volume":"13","author":[{"given":"Min","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunzhu","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guoqian","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junyi","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaqi","family":"Ni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,10,7]]},"reference":[{"key":"ref1","volume-title":"Report on the annual global survey 2023","year":"2024"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1177\/2040620712464509","article-title":"Factor VIII inhibitors in hemophilia A: rationale and latest evidence","volume":"4","author":"Witmer","year":"2013","journal-title":"Ther Adv Hematol"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/hae.14046","article-title":"WFH guidelines for the management of hemophilia, 3rd edition [Erratum in: Haemophilia. 2021;27(4):699]. doi: 10.1111\/hae.14308. PMID: 34110062","volume":"26","author":"Srivastava","year":"2020","journal-title":"Haemophilia"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1111\/hae.12246","article-title":"Randomized comparison of prophylaxis and on-demand regimens with FEIBA NF in the treatment of haemophilia a and B with inhibitors","volume":"20","author":"Antunes","year":"2014","journal-title":"Haemophilia"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"2404","DOI":"10.1016\/j.jtha.2024.06.002","article-title":"ISTH clinical practice guideline for treatment of congenital hemophilia A and B based on the grading of recommendations assessment, development, and evaluation methodology: considerations for practice management and implementation","volume":"22","author":"N\u00ed \u00c1inle","year":"2024","journal-title":"J Thromb Haemost"},{"key":"ref6","volume-title":"Emicizumab package insert","year":"2017"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"1697","DOI":"10.1007\/s40265-019-01200-2","article-title":"Emicizumab: a review in Haemophilia a","volume":"79","author":"Blair","year":"2019","journal-title":"Drugs"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"2231","DOI":"10.1182\/blood.2020009217","article-title":"Long-term outcomes with emicizumab prophylaxis for hemophilia A with or without FVIII inhibitors from the HAVEN 1-4 studies [Erratum in: Blood. 2023; 142(15):1329. doi: 10.1182\/blood.2023022214. PMID: 37824158]","volume":"137","author":"Callaghan","year":"2021","journal-title":"Blood"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1111\/hae.13618","article-title":"The effect of emicizumab prophylaxis on health-related outcomes in persons with haemophilia A with inhibitors: HAVEN 1 study","volume":"25","author":"Oldenburg","year":"2019","journal-title":"Haemophilia"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1056\/NEJMoa1703068","article-title":"Emicizumab prophylaxis in hemophilia A with inhibitors","volume":"377","author":"Oldenburg","year":"2017","journal-title":"N Engl J Med"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"115","DOI":"10.2147\/JBM.S288283","article-title":"Efficacy of rFVIIIFc versus Emicizumab for the treatment of patients with hemophilia A without inhibitors: matching-adjusted indirect comparison of A-LONG and HAVEN trials","volume":"12","author":"Klamroth","year":"2021","journal-title":"J Blood Med"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1080\/17474086.2023.2198207","article-title":"A real-world evidence analysis of the impact of switching from factor VIII to emicizumab prophylaxis in patients with hemophilia A without inhibitors","volume":"16","author":"Escobar","year":"2023","journal-title":"Expert Rev Hematol"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"457","DOI":"10.3111\/13696998.2015.1016228","article-title":"Burden of illness: direct and indirect costs among persons with hemophilia A in the United States","volume":"18","author":"Zhou","year":"2015","journal-title":"J Med Econ"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1111\/hae.14082","article-title":"The societal burden of haemophilia a. III - the potential impact of emicizumab on costs of haemophilia A in Australia","volume":"26","author":"Brown","year":"2020","journal-title":"Haemophilia"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1111\/hae.14347","article-title":"Real-world cost estimates of initiating emicizumab in US patients with haemophilia A","volume":"27","author":"Samelson-Jones","year":"2021","journal-title":"Haemophilia"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"667","DOI":"10.18553\/jmcp.2021.27.5.667","article-title":"The effectiveness and value of emicizumab and valoctocogene roxaparvovec for the management of hemophilia A without inhibitors","volume":"27","author":"Agboola","year":"2021","journal-title":"J Manag Care Spec Pharm"},{"key":"ref17","volume-title":"Official exchange rate","year":"2023"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.jval.2021.10.008","article-title":"Consolidated health economic evaluation reporting standards (CHEERS) 2022 explanation and elaboration: a report of the ISPOR CHEERS II good practices task force [Erratum in: Value Health. 2022; 25(6):1060. doi: 10.1016\/j.jval.2022.03.002. PMID: 35474251]","volume":"25","author":"Husereau","year":"2022","journal-title":"Value Health"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1097\/XEB.0000000000000063","article-title":"Conducting systematic reviews of economic evaluations","volume":"13","author":"Gomersall","year":"2015","journal-title":"Int J Evid Based Healthc"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"e8703","DOI":"10.5867\/medwave.2022.02.002118","article-title":"Cost-effectiveness study of prophylaxis with emicizumab versus bypassing agents in patients with severe hemophilia A in Peru","volume":"22","author":"Bitr\u00e1n","year":"2022","journal-title":"Medwave"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.vhri.2022.10.007","article-title":"Economic evaluation of immune tolerance induction in children with severe hemophilia A and high-responding inhibitors: a cost-effectiveness analysis of prophylaxis with emicizumab","volume":"34","author":"Camelo","year":"2023","journal-title":"Value Health Reg Issues"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1055\/s-0039-3401822","article-title":"Cost-effectiveness and budget impact of Emicizumab prophylaxis in Haemophilia A patients with inhibitors","volume":"120","author":"Cortesi","year":"2020","journal-title":"Thromb Haemost"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"e12","DOI":"10.1111\/hae.14143","article-title":"Cost-utility analysis of emicizumab prophylaxis in haemophilia A patients with factor VIII inhibitors in Korea","volume":"27","author":"Lee","year":"2021","journal-title":"Haemophilia"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1111\/hae.14129","article-title":"Cost-effectiveness of emicizumab vs bypassing agents in the prevention of bleeding episodes in haemophilia a patients with anti-FVIII inhibitors in France","volume":"27","author":"Polack","year":"2021","journal-title":"Haemophilia"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"e27303","DOI":"10.1097\/MD.0000000000027303","article-title":"A comparison between on-demand usage of rFVIIa vs prophylaxis use of emicizumab in high titer inhibitory hemophilia A patients in Iran: a cost-utility analysis","volume":"100","author":"Saiyarsarai","year":"2021","journal-title":"Medicine (Baltimore)"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"e27089","DOI":"10.1016\/j.heliyon.2024.e27089","article-title":"Budget impact and cost-utility analysis of prophylactic emicizumab versus on-demand bypassing agents for adolescent severe haemophilia A patients with inhibitors in India","volume":"10","author":"Krishnamoorthy","year":"2024","journal-title":"Heliyon"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.1111\/hae.15105","article-title":"Evaluating the benefits of emicizumab prophylaxis for haemophilia A with inhibitors: a cost-effectiveness and budget impact analysis in Thailand's upper-middle income setting","volume":"30","author":"Kengkla","year":"2024","journal-title":"Haemophilia"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2025016822","article-title":"Emicizumab for preventing intracranial hemorrhage in infants with severe hemophilia A: a cost-effectiveness analysis","author":"Glaeser-Khan","year":"2025","journal-title":"Blood Adv"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"e679","DOI":"10.1097\/HS9.0000000000000679","article-title":"Modeling benefits, costs, and affordability of a novel gene therapy in hemophilia A [Erratum in: Hemasphere. 2022; 6(3):e698. doi: 10.1097\/HS9.0000000000000698. PMID: 35187409]","volume":"6","author":"Ten Ham","year":"2022","journal-title":"Hema"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1111\/ejh.13901","article-title":"Cost-effectiveness of recombinant factor VIII fc versus emicizumab for prophylaxis in adults and adolescents with haemophilia a without inhibitors in the UK","volume":"110","author":"Kragh","year":"2023","journal-title":"Eur J Haematol"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1080\/13696998.2022.2115777","article-title":"Cost-minimization analysis of recombinant factor VIII fc versus emicizumab for treating patients with hemophilia A without inhibitors in Europe","volume":"25","author":"Mancuso","year":"2022","journal-title":"J Med Econ"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"E247","DOI":"10.1002\/ajh.27014","article-title":"Cost-effectiveness of prophylactic emicizumab versus prophylactic recombinant factor VIII in patients with moderate or mild hemophilia A without inhibitors in the United States","volume":"98","author":"Potnis","year":"2023","journal-title":"Am J Hematol"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1111\/hae.14921","article-title":"Cost-effectiveness analysis of emicizumab prophylaxis in patients with haemophilia A in India","volume":"30","author":"Seth","year":"2024","journal-title":"Haemophilia"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1111\/hae.14723","article-title":"Cost-utility analysis of emicizumab for the treatment of severe hemophilia A patients in Canada","volume":"29","author":"Yu","year":"2023","journal-title":"Haemophilia"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.18553\/jmcp.2020.19406","article-title":"Model of short- and long-term outcomes of Emicizumab prophylaxis treatment for persons with hemophilia A","volume":"26","author":"Zhou","year":"2020","journal-title":"J Manag Care Spec Pharm"},{"key":"ref36","volume-title":"Valoctocogene roxaparvovec package insert","year":"2023"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.vhri.2021.07.003","article-title":"Budget impact of Emicizumab for routine prophylaxis of bleeding episodes in patients with hemophilia A with inhibitors","volume":"28","author":"Watanabe","year":"2022","journal-title":"Value Health Reg Issues"},{"key":"ref38","author":"Tice","year":"2022"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.vhri.2023.11.013","article-title":"Assessment of extent and quality of Pharmacoeconomic studies in India using quality of health economic studies score: a targeted literature review","volume":"41","author":"Patel","year":"2024","journal-title":"Value Health Reg Issues."}],"container-title":["Frontiers in Public Health"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2025.1658760\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T05:34:29Z","timestamp":1759815269000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2025.1658760\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,7]]},"references-count":39,"alternative-id":["10.3389\/fpubh.2025.1658760"],"URL":"https:\/\/doi.org\/10.3389\/fpubh.2025.1658760","relation":{},"ISSN":["2296-2565"],"issn-type":[{"value":"2296-2565","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,7]]},"article-number":"1658760"}}